Shunichi Takiguchi1, Makoto Ayaori2, Emi Yakushiji1, Takafumi Nishida1, Kazuhiro Nakaya1, Makoto Sasaki1, Maki Iizuka1, Harumi Uto-Kondo1, Yoshio Terao1, Makiko Yogo1, Tomohiro Komatsu1, Masatsune Ogura3, Katsunori Ikewaki1. 1. From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.). 2. From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.) ayaori@ba2.so-net.ne.jp. 3. Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center, Osaka, Japan (M.O.).
Abstract
OBJECTIVE: Reverse cholesterol transport (RCT) is a major mechanism by which HDL (high-density lipoprotein) protects against atherosclerosis. Endothelial lipase (EL) reportedly reduces HDL levels, which, in theory, would increase atherosclerosis. However, it remains unclear whether EL affects RCT in vivo. APPROACH AND RESULTS: Adenoviral vectors expressing EL or luciferase were intravenously injected into mice, and a macrophage RCT assay was performed. As expected, hepatic EL overexpression markedly reduced HDL levels. In parallel, plasma 3H-cholesterol counts from the EL-expressing mice decreased by 85% compared with control. Surprisingly, there was no difference in fecal 3H-cholesterol excretion between the groups. Kinetic studies revealed increased catabolism/hepatic uptake of 3HDL-cholesteryl ether, resulting in no change in fecal HDL-cholesteryl ester excretion in the mice. To explore underlying mechanisms for the preservation of RCT despite low HDL levels in the EL-expressing mice, we investigated the effects of hepatic SR-BI (scavenger receptor class B type I) knockdown. RCT assay revealed that knockdown of SR-BI alone reduced fecal excretion of macrophage-derived 3H-cholesterol. Interestingly, hepatic EL overexpression under SR-BI inhibition further attenuated fecal tracer counts as compared with control. Finally, we observed that EL overexpression enhanced in vivo RCT under pharmacological inhibition of hepatic ABCA1 (ATP-binding cassette transporter A1) by probucol. CONCLUSIONS: Hepatic EL expression compensates for reduced macrophage-derived cholesterol efflux to plasma because of low HDL levels by promoting cholesterol excretion to bile/feces via an SR-BI pathway, maintaining overall RCT in vivo. In contrast, EL-modified HDL might negatively regulate RCT via hepatic ABCA1. Despite extreme hypoalphalipoproteinemia, RCT is maintained in EL-expressing mice via SR-BI/ABCA1-dependent pathways.
OBJECTIVE: Reverse cholesterol transport (RCT) is a major mechanism by which HDL (high-density lipoprotein) protects against atherosclerosis. Endothelial lipase (EL) reportedly reduces HDL levels, which, in theory, would increase atherosclerosis. However, it remains unclear whether EL affects RCT in vivo. APPROACH AND RESULTS: Adenoviral vectors expressing EL or luciferase were intravenously injected into mice, and a macrophage RCT assay was performed. As expected, hepatic EL overexpression markedly reduced HDL levels. In parallel, plasma 3H-cholesterol counts from the EL-expressing mice decreased by 85% compared with control. Surprisingly, there was no difference in fecal 3H-cholesterol excretion between the groups. Kinetic studies revealed increased catabolism/hepatic uptake of 3HDL-cholesteryl ether, resulting in no change in fecal HDL-cholesteryl ester excretion in the mice. To explore underlying mechanisms for the preservation of RCT despite low HDL levels in the EL-expressing mice, we investigated the effects of hepatic SR-BI (scavenger receptor class B type I) knockdown. RCT assay revealed that knockdown of SR-BI alone reduced fecal excretion of macrophage-derived 3H-cholesterol. Interestingly, hepatic EL overexpression under SR-BI inhibition further attenuated fecal tracer counts as compared with control. Finally, we observed that EL overexpression enhanced in vivo RCT under pharmacological inhibition of hepatic ABCA1 (ATP-binding cassette transporter A1) by probucol. CONCLUSIONS: Hepatic EL expression compensates for reduced macrophage-derived cholesterol efflux to plasma because of low HDL levels by promoting cholesterol excretion to bile/feces via an SR-BI pathway, maintaining overall RCT in vivo. In contrast, EL-modified HDL might negatively regulate RCT via hepatic ABCA1. Despite extreme hypoalphalipoproteinemia, RCT is maintained in EL-expressing mice via SR-BI/ABCA1-dependent pathways.
Authors: Mary G McCoy; Gwo-Shing Sun; Dawn Marchadier; Cyrille Maugeais; Jane M Glick; Daniel J Rader Journal: J Lipid Res Date: 2002-06 Impact factor: 5.922
Authors: Thomas J F Nieland; Marsha Penman; Limor Dori; Monty Krieger; Tomas Kirchhausen Journal: Proc Natl Acad Sci U S A Date: 2002-11-18 Impact factor: 11.205
Authors: Weijun Jin; Ilia V Fuki; Nabil G Seidah; Suzanne Benjannet; Jane M Glick; Daniel J Rader Journal: J Biol Chem Date: 2005-08-18 Impact factor: 5.157
Authors: Roshni R Singaraja; Suthesh Sivapalaratnam; Kees Hovingh; Marie-Pierre Dubé; José Castro-Perez; Heidi L Collins; Steven J Adelman; Meliana Riwanto; Jasmin Manz; Brian Hubbard; Ian Tietjen; Kenny Wong; Lyndon J Mitnaul; Margaret van Heek; Linus Lin; Thomas A Roddy; Jason McEwen; Geesje Dallinge-Thie; Leonie van Vark-van der Zee; Germaine Verwoert; Michael Winther; Cornelia van Duijn; Albert Hofman; Mieke D Trip; A David Marais; Bela Asztalos; Ulf Landmesser; Eric Sijbrands; John J Kastelein; Michael R Hayden Journal: Circ Cardiovasc Genet Date: 2012-12-14
Authors: Andrew C Edmondson; Robert J Brown; Sekar Kathiresan; L Adrienne Cupples; Serkalem Demissie; Alisa Knodle Manning; Majken K Jensen; Eric B Rimm; Jian Wang; Amrith Rodrigues; Vaneeta Bamba; Sumeet A Khetarpal; Megan L Wolfe; Stephanie Derohannessian; Mingyao Li; Muredach P Reilly; Jens Aberle; David Evans; Robert A Hegele; Daniel J Rader Journal: J Clin Invest Date: 2009-03-16 Impact factor: 14.808
Authors: Ilia V Fuki; Nadine Blanchard; Weijun Jin; Dawn H L Marchadier; John S Millar; Jane M Glick; Daniel J Rader Journal: J Biol Chem Date: 2003-06-16 Impact factor: 5.157
Authors: Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2019-12-23 Impact factor: 8.311
Authors: Milessa Silva Afonso; Roberta Marcondes Machado; Maria Silvia Lavrador; Eder Carlos Rocha Quintao; Kathryn J Moore; Ana Maria Lottenberg Journal: Nutrients Date: 2018-06-13 Impact factor: 5.717